Printer friendly version

ID: 629

Type of submission: Oral

Conference track: Research

Topics: Opioid Substitution Therapy Programmes; Viral Hepatitis and Tuberculosis

Presenting author: Perrine Roux

Presenting author biography:

1996-2003 Pharm.D., Bordeaux 2002-2003 M.Sc. in Public Health, University Paris VI 2006-2007 M.Sc. in Sociology - School of Social Sciences (EHESS), Paris 2007-2010 Ph.D. in Public Health INSERM U912, Marseille 2010-2012 Post-doctoral fellowship at Columbia University, SURC, NY 2012-present Researcher INSERM, SESSTIM-INSERM U912, Marseille

Acceptability of intravenous buprenorphine as an opioid treatment: results from a community-based survey among people who inject drugs with high-risk behaviors in France

Perrine Roux, Daniela Rojas Castro, Khadim Ndiaye, Virginie Laporte, Marion Mora, Gwenaelle Maradan, Stephane Morel, Bruno Spire, Patrizia Carrieri

Aims: Injectable opioids are an interesting option for people who inject drugs (PWID) who do not respond to oral Opioid Maintenance Treatment. To date, intravenous (IV) buprenorphine - a safer drug than full-opioid agonists in terms of overdose risk - has never been tested in a clinical trial for opioid dependence. This survey was designed to better understand the eligibility profile of PWID for IV buprenorphine, and their acceptability of it. Design and Methods: This survey consisted in a cross-sectional questionnaire completed either through face-to-face interviews or online. Among the 557 PWID enrolled, we selected respondents who were eligible for IV opioid treatment and studied both their socio-demographic and behavioral profile and their acceptability of IV buprenorphine treatment. Results: Among the selected 371 participants, with respect to opioid use, 58% mainly injected buprenorphine, 15% heroin, 17% morphine sulfate and 10% other opioids. Seventy eight percent of the sample reported that they would be willing to receive IV buprenorphine. Multivariate analysis showed that those who reported having more than 5 injection-related complications and those who injected buprenorphine or heroin were more likely to accept IV buprenorphine. Discussion and Conclusions: PWID acceptability for IV buprenorphine as a treatment was high. The results of this preliminary study provide useful information for the development of a clinical trial for IV buprenorphine treatment. In addition, they show that buprenorphine may be unacceptable to some PWID, such as those injecting morphine sulfate, but acceptable to heroin injectors and to those with multiple injection-related complications.